AAAAAA

   
Results: 1-7 |
Results: 7
MAXIMIZING RADIOTRACER DELIVERY TO EXPERIMENTAL ATHEROSCLEROTIC LESIONS WITH HIGH-DOSE, NEGATIVE CHARGE-MODIFIED Z2D3 ANTIBODY FOR IMMUNOSCINTIGRAPHIC TARGETING
Authors: NARULA J PETROV A DITLOW C PAK KY CHEN FW KHAW BA
Citation: J. Narula et al., MAXIMIZING RADIOTRACER DELIVERY TO EXPERIMENTAL ATHEROSCLEROTIC LESIONS WITH HIGH-DOSE, NEGATIVE CHARGE-MODIFIED Z2D3 ANTIBODY FOR IMMUNOSCINTIGRAPHIC TARGETING, Journal of nuclear cardiology, 4(3), 1997, pp. 226-233
NONINVASIVE DETECTION OF ATHEROSCLEROTIC LESIONS BY TC-99M-BASED IMMUNOSCINTIGRAPHIC TARGETING OF PROLIFERATING SMOOTH-MUSCLE CELLS
Authors: NARULA J PETROV A PAK KY DITLOW C CHEN F KHAW BA
Citation: J. Narula et al., NONINVASIVE DETECTION OF ATHEROSCLEROTIC LESIONS BY TC-99M-BASED IMMUNOSCINTIGRAPHIC TARGETING OF PROLIFERATING SMOOTH-MUSCLE CELLS, Chest, 111(6), 1997, pp. 1684-1690
GAMMA-IMAGING OF ATHEROSCLEROTIC LESIONS - THE ROLE OF ANTIBODY-AFFINITY IN IN-VIVO TARGET LOCALIZATION
Authors: NARULA J PETROV A ODONNELL SM DITLOW C PIESLAK I DILLEY J CHEN F KHAW BA
Citation: J. Narula et al., GAMMA-IMAGING OF ATHEROSCLEROTIC LESIONS - THE ROLE OF ANTIBODY-AFFINITY IN IN-VIVO TARGET LOCALIZATION, Journal of nuclear cardiology, 3(3), 1996, pp. 231-241
IN-111 CHIMERIC NEGATIVE-CHARGED-Z2D3 PL-F(AB')(2) IMAGING OF PROLIFERATING SMOOTH-MUSCLE CELL IN ATHEROSCLEROTIC LESIONS
Authors: CARRIO I PIERI PL NARULA J PRAT L PEDRINI L RIVA P SARTI G PAK C DITLOW C CHEN F KHAW BA
Citation: I. Carrio et al., IN-111 CHIMERIC NEGATIVE-CHARGED-Z2D3 PL-F(AB')(2) IMAGING OF PROLIFERATING SMOOTH-MUSCLE CELL IN ATHEROSCLEROTIC LESIONS, The Journal of nuclear medicine, 37(5), 1996, pp. 187-187
A DIABODY FOR IMAGING OF ATHEROSCLEROTIC PLAQUES
Authors: ADAIR J ARMOUR K CARR F DITLOW C CHEN F HOLLIGER P WINTER G HARRIS W
Citation: J. Adair et al., A DIABODY FOR IMAGING OF ATHEROSCLEROTIC PLAQUES, Journal of cellular biochemistry, 1994, pp. 209-209
EARLIER EXPERIMENTAL ATHEROSCLEROTIC LESION VISUALIZATION WITH HIGH RADIOSPECIFIC-ACTIVITY, NEGATIVE CHARGE-MODIFIED CHIMERIC Z2D3 F(AB')(2) (AT 24 HOURS) VERSUS CONVENTIONALLY LABELED-ANTIBODY (AT 48 HOURS)
Authors: NARULA J PETROV A DITLOW C DILLEY J PIESLAK I CHEN FW KHAW BA
Citation: J. Narula et al., EARLIER EXPERIMENTAL ATHEROSCLEROTIC LESION VISUALIZATION WITH HIGH RADIOSPECIFIC-ACTIVITY, NEGATIVE CHARGE-MODIFIED CHIMERIC Z2D3 F(AB')(2) (AT 24 HOURS) VERSUS CONVENTIONALLY LABELED-ANTIBODY (AT 48 HOURS), The Journal of nuclear medicine, 35(5), 1994, pp. 160000098-160000098
LOCALIZATION OF EXPERIMENTAL ATHEROSCLEROTIC LESIONS WITH NEGATIVELY-CHARGED POLYMER-MODIFIED CHIMERIC ANTIBODY SPECIFIC FOR PROLIFERATING NEOINTIMAL SMOOTH-MUSCLE CELLS
Authors: NARULA J PETROV A DITLOW C CHEN F KHAW BA
Citation: J. Narula et al., LOCALIZATION OF EXPERIMENTAL ATHEROSCLEROTIC LESIONS WITH NEGATIVELY-CHARGED POLYMER-MODIFIED CHIMERIC ANTIBODY SPECIFIC FOR PROLIFERATING NEOINTIMAL SMOOTH-MUSCLE CELLS, Circulation, 88(4), 1993, pp. 250-250
Risultati: 1-7 |